Sector News

DSM acquires BioCare Copenhagen

December 26, 2017
Life sciences

Royal DSM, a global science-based company active in health, nutrition and materials, announces it has acquired BioCare Copenhagen A/S, based in Copenhagen (Denmark).

With the acquisition, DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year. Financial details will not be disclosed at this time.

BioCare Copenhagen is a privately-held company founded in 2012, focused on probiotics and specialized in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections, and immunity. The company offers high-quality white label probiotic supplements and complete product concepts with strong consumer appeal. BioCare Copenhagen has multi-market distribution agreements with a number of leading dietary supplements and pharmaceutical companies and has launched products in over 40 countries worldwide.

DSM already has a strong position in gut health solutions with its Culturelle® product range, the number-one-selling probiotic dietary supplement consumer brand globally, as well as with its ingredient brands Oatwell® and Tolerase®. The company sees further growth potential in gut health ingredients beyond the established indications for digestive health and immune health. Fields increasingly recognized as being impacted by the gut microbiome include the gut-brain axis, metabolic health and heart health. DSM’s ambition in addressing the gut microbiome and its portfolio of nutritional ingredients are very synergetic with BioCare Copenhagen’s approach and products, and the combination is well-catered to address the existing and emerging gut health areas.

Source: DSM

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach